FRANKFURT/LONDON (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.
Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells.Gene therapy has seen more than 20 years of experiments and a series of disappoint...
22:35 Bryce Harper's request for record $400 million deal too much for Nationals: report2
20:38 $400 Million Man: Washington Nationals' Bryce Harper demands record deal14
23:35 50 Cent $14.5 Mil from Lawyers He Accused Of Sleek Audio Screw Job11
03:00 Carrier incentives stir debate over 'rewarding' offshoring15